Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis

被引:17
作者
Anderson, Tarah M. Regan [1 ,2 ,3 ]
Ma, Shihong [4 ]
Kerkvliet, Carlos Perez [1 ,2 ,3 ]
Peng, Yan [4 ]
Helle, Taylor M. [1 ,2 ,3 ]
Krutilina, Raisa I. [5 ,8 ]
Raj, Ganesh V. [4 ]
Cidlowski, John A. [5 ]
Ostrander, Julie H. [1 ,2 ,3 ]
Schwertfeger, Kathryn L. [6 ,7 ]
Seagroves, Tiffany N. [8 ]
Lange, Carol A. [1 ,2 ,3 ]
机构
[1] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Pharmacol, Div Hematol Oncol & Transplantat, 3-249 Millard Hall, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Masonic Canc Ctr, MMC 806 Mayo 8806A,420 Delaware St SE, Minneapolis, MN 55455 USA
[4] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA
[5] NIEHS, Lab Signal Transduct, NIH, US Dept HHS, POB 12233, Res Triangle Pk, NC 27709 USA
[6] Univ Minnesota, Dept Lab Med & Pathol, Masonic Canc Ctr, Minneapolis, MN 55455 USA
[7] Univ Minnesota, Ctr Immunol, Minneapolis, MN USA
[8] Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA
关键词
TUMOR KINASE BRK/PTK6; BREAST-CANCER; GLUCOCORTICOID-RECEPTOR; ANOIKIS RESISTANCE; ESTROGEN-RECEPTOR; ACTIVATION; DEGRADATION; INHIBITION; EXPRESSION; OVEREXPRESSION;
D O I
10.1158/1541-7786.MCR-18-0410
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The metastatic cascade is a complex process that requires cancer cells to survive despite conditions of high physiologic stress. Previously, cooperation between the glucocorticoid receptor (GR) and hypoxia-inducible factors (HIF) was reported as a point of convergence for host and cellular stress signaling. These studies indicated p38 MAPK-dependent phosphorylation of GR on Ser134 and subsequent p-GR/HIF-dependent induction of breast tumor kinase (PTK6/Brk), as a mediator of aggressive cancer phenotypes. Herein, p-Ser134 GR was quantified in human primary breast tumors (n = 281) and the levels of p-GR were increased in triplenegative breast cancer (TNBC) relative to luminal breast cancer. Brk was robustly induced following exposure of TNBC model systems to chemotherapeutic agents (Taxol or 5-fluorouracil) and growth in suspension [ultra-low attachment (ULA)]. Notably, both Taxol and ULA resulted in upregulation of the Aryl hydrocarbon receptor (AhR), a known mediator of cancer prosurvival phenotypes. Mecha-nistically, AhR and GR copurified and following chemotherapy and ULA, these factors assembled at the Brk promoter and induced Brk expression in an HIF-dependent manner. Furthermore, Brk expression was upregulated in Taxol-resistant breast cancer (MCF-7) models. Ultimately, Brk was critical for TNBC cell proliferation and survival during Taxol treatment and in the context of ULA as well as for basal cancer cell migration, acquired biological phenotypes that enable cancer cells to successfully complete the metastatic cascade. These studies nominate AhR as a p-GR binding partner and reveal ways to target epigenetic events such as adaptive and stress-induced acquisition of cancer skill sets required for metastatic cancer spread. Implication: Breast cancer cells enlist intracellular stress response pathways that evade chemotherapy by increasing cancer cell survival and promoting migratory phenotypes. (C) 2018 AACR.
引用
收藏
页码:1761 / 1772
页数:12
相关论文
共 50 条
  • [31] Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR
    Li, X.
    Lu, Y.
    Liang, K.
    Hsu, J-M
    Albarracin, C.
    Mills, G. B.
    Hung, M-C
    Fan, Z.
    [J]. ONCOGENE, 2012, 31 (40) : 4372 - 4383
  • [32] Dexamethasone induces docetaxel and cisplatin resistance-partially through up-regulating Kruppel-like factor 5 in triple-negative breast cancer
    Li, Zhen
    Dong, Jian
    Zou, Tianning
    Du, Chengzhi
    Li, Siyuan
    Chen, Ceshi
    Liu, Rong
    Wang, Kunhua
    [J]. ONCOTARGET, 2017, 8 (07) : 11555 - 11565
  • [33] Hypoxia-inducible factor 1 mediates intermittent hypoxia-induced migration of human breast cancer MDA-MB-231 cells
    Liu, Litao
    Liu, Wenlan
    Wang, Lili
    Zhu, Ting
    Zhong, Jianhua
    Xie, Ni
    [J]. ONCOLOGY LETTERS, 2017, 14 (06) : 7715 - 7722
  • [34] A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer
    Nanda, Rita
    Stringer-Reasor, Erica M.
    Saha, Poornima
    Kocherginsky, Masha
    Gibson, Jean
    Libao, Bernadette
    Hoffman, Philip C.
    Obeid, Elias
    Merkel, Douglas E.
    Khramtsova, Galina
    Skor, Maxwell
    Krausz, Thomas
    Cohen, Ronald N.
    Ratain, Mark J.
    Fleming, Gini F.
    Conzen, Suzanne D.
    [J]. SPRINGERPLUS, 2016, 5
  • [35] Brk/PTK6 signaling in normal and cancer cell models
    Ostrander, Julie H.
    Daniel, Andrea R.
    Lange, Carol A.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2010, 10 (06) : 662 - 669
  • [36] Breast tumor kinase (Protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells
    Ostrander, Julie Hanson
    Daniel, Andrea R.
    Lofgren, Kristopher
    Kleer, Celina G.
    Lange, Carol A.
    [J]. CANCER RESEARCH, 2007, 67 (09) : 4199 - 4209
  • [37] Activation of the Glucocorticoid Receptor Is Associated with Poor Prognosis in Estrogen Receptor-Negative Breast Cancer
    Pan, Deng
    Kocherginsky, Masha
    Conzen, Suzanne D.
    [J]. CANCER RESEARCH, 2011, 71 (20) : 6360 - 6370
  • [38] Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis
    Pang, Diana
    Kocherginsky, Masha
    Krausz, Thomas
    Kim, So-Young
    D Conzen, Suzanne
    [J]. CANCER BIOLOGY & THERAPY, 2006, 5 (08) : 933 - 940
  • [39] Anoikis molecular pathways and its role in cancer progression
    Paoli, Paolo
    Giannoni, Elisa
    Chiarugi, Paola
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2013, 1833 (12): : 3481 - 3498
  • [40] PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors
    Peng, Maoyu
    Emmadi, Rajyasree
    Wang, Zebin
    Wiley, Elizabeth L.
    Gann, Peter H.
    Khan, Seema A.
    Banerji, Nilanjana
    McDonald, William
    Asztalos, Szilard
    Pham, Thao N. D.
    Tonetti, Debra A.
    Tyner, Angela L.
    [J]. ONCOTARGET, 2014, 5 (15) : 6038 - 6048